Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quadrivalent influenza mRNA vaccine MRT5424
- Development stage
- Phase 2
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
Quadrivalent influenza mRNA vaccine MRT5424 is an investigational messenger RNA (mRNA) vaccine developed to provide immunization against seasonal influenza. It encodes antigens from four different strains of the influenza virus, corresponding to the standard composition of a quadrivalent flu vaccine. The mechanism of action involves delivery of antigen-encoding mRNA into host cells via intramuscular injection; these cells then produce viral proteins that elicit an immune response, generating protective antibodies against the targeted strains. The primary indication is prevention of seasonal influenza in adults aged 18 years and older. This candidate is being developed by Sanofi Pasteur and has been evaluated in Phase 1/2 clinical trials for safety and immunogenicity compared to standard-dose, high-dose (for adults ≥65), or recombinant protein-based flu vaccines[1][2][5].
- Other names
- quadrivalent influenza mRNA vaccine MRT5424quadrivalent influenza mRNA vaccine
02
Targets
HA0 (Influenza B virus hemagglutinin)HA (Hemagglutinin)
Beyond the preview
Go deeper on quadrivalent influenza mRNA vaccine MRT5424.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quadrivalent influenza mRNA vaccine MRT5424.